Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study
Summary Background: Studies have shown that weight loss can have a favourable effect upon non‐alcoholic fatty liver disease (NAFLD). However, the most effective means of achieving weight loss and safety profile of lipid‐lowering drugs in the presence of NAFLD is unknown. Aim: To investigate the ef...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical practice (Esher) 2008-03, Vol.62 (3), p.374-381 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 381 |
|---|---|
| container_issue | 3 |
| container_start_page | 374 |
| container_title | International journal of clinical practice (Esher) |
| container_volume | 62 |
| creator | Riley, P. Sudarshi, D. Johal, M. Benedict, A. Panteli, J. Crook, M. O'Donohue, J. |
| description | Summary
Background: Studies have shown that weight loss can have a favourable effect upon non‐alcoholic fatty liver disease (NAFLD). However, the most effective means of achieving weight loss and safety profile of lipid‐lowering drugs in the presence of NAFLD is unknown.
Aim: To investigate the effect of dietary advice and lipid‐lowering drugs, particularly statins, on patients with NAFLD and dyslipidaemia.
Design: Observational records based study.
Methods: We studied 71 patients with NAFLD and dyslipidaemia diagnosed and treated between 1996 and 2002 at University Hospital Lewisham. Some were referred to a dietician for weight loss advice as part of their management. After treatment all patients were assessed for changes in weight, serum alanine transaminase (ALT) and serum lipids including serum cholesterol, serum high density lipoprotein (HDL) and serum triglycerides.
Results: Thirty‐seven male and 34 female patients with NAFLD and dyslipidaemia were followed up for a mean period of 440 ± 374 days (median 335). Regression analysis revealed a significant association between changes in weight and changes in serum ALT (p |
| doi_str_mv | 10.1111/j.1742-1241.2007.01666.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70288228</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1423391431</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3796-9f5d9b46778596971004b48352855529b6c1f121689e8ba61b0621f3204880af3</originalsourceid><addsrcrecordid>eNpdkV2L1DAUhou4uOvqX5Ag6JXtJmnz5YUgs7ofLCqijngT0jR10s20Y5Ku039v6syOYG5y4Dx5cjhvlgEEC5TOWVcgVuEc4QoVGEJWQEQpLbYPspND42GqS8pzAkt0nD0OoYMQE8Lho-wYcQwR4ugk65bG_lxF4IYQXoHGmqj8BFRzZ7UBqm9AiCraHsSV8WozgVT2Q58rp4fV4KwGrYpxAs7eGZ-eB6OCeQ0U8Cb6IWyMjqmTJGMzPcmOWuWCebq_T7Ov7999WVzmNx8vrhZvb3JdMkFz0ZJG1BVljBNBBUMQVnXFS4I5IQSLmmrUIowoF4bXiqIaUozaEsOKc6ja8jR7ufNu_PBrNCHKtQ3aOKd6M4xBMog5x5gn8Pl_YDeMvk-zSYyFQFxQlqBne2is16aRG2_XaUXyfoUJeLEHVNDKtV712oYDl6gyeebf3uy439aZ6Z8HyjlS2ck5OTknJ-dI5d9I5VZeXS8-zWUS5DuBDdFsDwLlb2WakxG5_HAhL5fk_Mf5t-_yc_kHdpOhzg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>229918967</pqid></control><display><type>article</type><title>Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Riley, P. ; Sudarshi, D. ; Johal, M. ; Benedict, A. ; Panteli, J. ; Crook, M. ; O'Donohue, J.</creator><creatorcontrib>Riley, P. ; Sudarshi, D. ; Johal, M. ; Benedict, A. ; Panteli, J. ; Crook, M. ; O'Donohue, J.</creatorcontrib><description>Summary
Background: Studies have shown that weight loss can have a favourable effect upon non‐alcoholic fatty liver disease (NAFLD). However, the most effective means of achieving weight loss and safety profile of lipid‐lowering drugs in the presence of NAFLD is unknown.
Aim: To investigate the effect of dietary advice and lipid‐lowering drugs, particularly statins, on patients with NAFLD and dyslipidaemia.
Design: Observational records based study.
Methods: We studied 71 patients with NAFLD and dyslipidaemia diagnosed and treated between 1996 and 2002 at University Hospital Lewisham. Some were referred to a dietician for weight loss advice as part of their management. After treatment all patients were assessed for changes in weight, serum alanine transaminase (ALT) and serum lipids including serum cholesterol, serum high density lipoprotein (HDL) and serum triglycerides.
Results: Thirty‐seven male and 34 female patients with NAFLD and dyslipidaemia were followed up for a mean period of 440 ± 374 days (median 335). Regression analysis revealed a significant association between changes in weight and changes in serum ALT (p < 0.039). Dietary advice failed to reduce body weight but significantly lowered the serum cholesterol to HDL ratio (p = 0.05). Only 15.4% of patients taking statins experienced a rise in serum ALT ≥ 40 U/l, and in each case the rise was transient, returning near baseline or below without discontinuation of statin treatment.
Conclusions: Weight loss appears to improve NAFLD, and dietary advice and lipid‐lowering drugs may be beneficial for patients with NAFLD and dyslipidaemia even if weight loss is not achieved. Statins appear to be safe and efficacious in this group.</description><identifier>ISSN: 1368-5031</identifier><identifier>EISSN: 1742-1241</identifier><identifier>DOI: 10.1111/j.1742-1241.2007.01666.x</identifier><identifier>PMID: 18201181</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Alanine Transaminase - blood ; Biological and medical sciences ; Clinical outcomes ; Cohort Studies ; Drug therapy ; Dyslipidemias - diet therapy ; Dyslipidemias - drug therapy ; Fatty Liver - diet therapy ; Fatty Liver - drug therapy ; Female ; General aspects ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Life Style ; Lipids - blood ; Liver diseases ; Male ; Medical sciences ; Metabolic diseases ; Middle Aged ; Nutrition therapy ; Regression Analysis ; Retrospective Studies ; Statins ; Treatment Outcome ; Weight control ; Weight Loss - physiology</subject><ispartof>International journal of clinical practice (Esher), 2008-03, Vol.62 (3), p.374-381</ispartof><rights>2008 The Authors</rights><rights>2008 INIST-CNRS</rights><rights>Journal compilation © 2008 Blackwell Publishing Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3796-9f5d9b46778596971004b48352855529b6c1f121689e8ba61b0621f3204880af3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1742-1241.2007.01666.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1742-1241.2007.01666.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20139678$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18201181$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Riley, P.</creatorcontrib><creatorcontrib>Sudarshi, D.</creatorcontrib><creatorcontrib>Johal, M.</creatorcontrib><creatorcontrib>Benedict, A.</creatorcontrib><creatorcontrib>Panteli, J.</creatorcontrib><creatorcontrib>Crook, M.</creatorcontrib><creatorcontrib>O'Donohue, J.</creatorcontrib><title>Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study</title><title>International journal of clinical practice (Esher)</title><addtitle>Int J Clin Pract</addtitle><description>Summary
Background: Studies have shown that weight loss can have a favourable effect upon non‐alcoholic fatty liver disease (NAFLD). However, the most effective means of achieving weight loss and safety profile of lipid‐lowering drugs in the presence of NAFLD is unknown.
Aim: To investigate the effect of dietary advice and lipid‐lowering drugs, particularly statins, on patients with NAFLD and dyslipidaemia.
Design: Observational records based study.
Methods: We studied 71 patients with NAFLD and dyslipidaemia diagnosed and treated between 1996 and 2002 at University Hospital Lewisham. Some were referred to a dietician for weight loss advice as part of their management. After treatment all patients were assessed for changes in weight, serum alanine transaminase (ALT) and serum lipids including serum cholesterol, serum high density lipoprotein (HDL) and serum triglycerides.
Results: Thirty‐seven male and 34 female patients with NAFLD and dyslipidaemia were followed up for a mean period of 440 ± 374 days (median 335). Regression analysis revealed a significant association between changes in weight and changes in serum ALT (p < 0.039). Dietary advice failed to reduce body weight but significantly lowered the serum cholesterol to HDL ratio (p = 0.05). Only 15.4% of patients taking statins experienced a rise in serum ALT ≥ 40 U/l, and in each case the rise was transient, returning near baseline or below without discontinuation of statin treatment.
Conclusions: Weight loss appears to improve NAFLD, and dietary advice and lipid‐lowering drugs may be beneficial for patients with NAFLD and dyslipidaemia even if weight loss is not achieved. Statins appear to be safe and efficacious in this group.</description><subject>Alanine Transaminase - blood</subject><subject>Biological and medical sciences</subject><subject>Clinical outcomes</subject><subject>Cohort Studies</subject><subject>Drug therapy</subject><subject>Dyslipidemias - diet therapy</subject><subject>Dyslipidemias - drug therapy</subject><subject>Fatty Liver - diet therapy</subject><subject>Fatty Liver - drug therapy</subject><subject>Female</subject><subject>General aspects</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Life Style</subject><subject>Lipids - blood</subject><subject>Liver diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Middle Aged</subject><subject>Nutrition therapy</subject><subject>Regression Analysis</subject><subject>Retrospective Studies</subject><subject>Statins</subject><subject>Treatment Outcome</subject><subject>Weight control</subject><subject>Weight Loss - physiology</subject><issn>1368-5031</issn><issn>1742-1241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkV2L1DAUhou4uOvqX5Ag6JXtJmnz5YUgs7ofLCqijngT0jR10s20Y5Ku039v6syOYG5y4Dx5cjhvlgEEC5TOWVcgVuEc4QoVGEJWQEQpLbYPspND42GqS8pzAkt0nD0OoYMQE8Lho-wYcQwR4ugk65bG_lxF4IYQXoHGmqj8BFRzZ7UBqm9AiCraHsSV8WozgVT2Q58rp4fV4KwGrYpxAs7eGZ-eB6OCeQ0U8Cb6IWyMjqmTJGMzPcmOWuWCebq_T7Ov7999WVzmNx8vrhZvb3JdMkFz0ZJG1BVljBNBBUMQVnXFS4I5IQSLmmrUIowoF4bXiqIaUozaEsOKc6ja8jR7ufNu_PBrNCHKtQ3aOKd6M4xBMog5x5gn8Pl_YDeMvk-zSYyFQFxQlqBne2is16aRG2_XaUXyfoUJeLEHVNDKtV712oYDl6gyeebf3uy439aZ6Z8HyjlS2ck5OTknJ-dI5d9I5VZeXS8-zWUS5DuBDdFsDwLlb2WakxG5_HAhL5fk_Mf5t-_yc_kHdpOhzg</recordid><startdate>200803</startdate><enddate>200803</enddate><creator>Riley, P.</creator><creator>Sudarshi, D.</creator><creator>Johal, M.</creator><creator>Benedict, A.</creator><creator>Panteli, J.</creator><creator>Crook, M.</creator><creator>O'Donohue, J.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><general>Hindawi Limited</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>200803</creationdate><title>Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study</title><author>Riley, P. ; Sudarshi, D. ; Johal, M. ; Benedict, A. ; Panteli, J. ; Crook, M. ; O'Donohue, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3796-9f5d9b46778596971004b48352855529b6c1f121689e8ba61b0621f3204880af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Alanine Transaminase - blood</topic><topic>Biological and medical sciences</topic><topic>Clinical outcomes</topic><topic>Cohort Studies</topic><topic>Drug therapy</topic><topic>Dyslipidemias - diet therapy</topic><topic>Dyslipidemias - drug therapy</topic><topic>Fatty Liver - diet therapy</topic><topic>Fatty Liver - drug therapy</topic><topic>Female</topic><topic>General aspects</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Life Style</topic><topic>Lipids - blood</topic><topic>Liver diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Middle Aged</topic><topic>Nutrition therapy</topic><topic>Regression Analysis</topic><topic>Retrospective Studies</topic><topic>Statins</topic><topic>Treatment Outcome</topic><topic>Weight control</topic><topic>Weight Loss - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Riley, P.</creatorcontrib><creatorcontrib>Sudarshi, D.</creatorcontrib><creatorcontrib>Johal, M.</creatorcontrib><creatorcontrib>Benedict, A.</creatorcontrib><creatorcontrib>Panteli, J.</creatorcontrib><creatorcontrib>Crook, M.</creatorcontrib><creatorcontrib>O'Donohue, J.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical practice (Esher)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Riley, P.</au><au>Sudarshi, D.</au><au>Johal, M.</au><au>Benedict, A.</au><au>Panteli, J.</au><au>Crook, M.</au><au>O'Donohue, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study</atitle><jtitle>International journal of clinical practice (Esher)</jtitle><addtitle>Int J Clin Pract</addtitle><date>2008-03</date><risdate>2008</risdate><volume>62</volume><issue>3</issue><spage>374</spage><epage>381</epage><pages>374-381</pages><issn>1368-5031</issn><eissn>1742-1241</eissn><abstract>Summary
Background: Studies have shown that weight loss can have a favourable effect upon non‐alcoholic fatty liver disease (NAFLD). However, the most effective means of achieving weight loss and safety profile of lipid‐lowering drugs in the presence of NAFLD is unknown.
Aim: To investigate the effect of dietary advice and lipid‐lowering drugs, particularly statins, on patients with NAFLD and dyslipidaemia.
Design: Observational records based study.
Methods: We studied 71 patients with NAFLD and dyslipidaemia diagnosed and treated between 1996 and 2002 at University Hospital Lewisham. Some were referred to a dietician for weight loss advice as part of their management. After treatment all patients were assessed for changes in weight, serum alanine transaminase (ALT) and serum lipids including serum cholesterol, serum high density lipoprotein (HDL) and serum triglycerides.
Results: Thirty‐seven male and 34 female patients with NAFLD and dyslipidaemia were followed up for a mean period of 440 ± 374 days (median 335). Regression analysis revealed a significant association between changes in weight and changes in serum ALT (p < 0.039). Dietary advice failed to reduce body weight but significantly lowered the serum cholesterol to HDL ratio (p = 0.05). Only 15.4% of patients taking statins experienced a rise in serum ALT ≥ 40 U/l, and in each case the rise was transient, returning near baseline or below without discontinuation of statin treatment.
Conclusions: Weight loss appears to improve NAFLD, and dietary advice and lipid‐lowering drugs may be beneficial for patients with NAFLD and dyslipidaemia even if weight loss is not achieved. Statins appear to be safe and efficacious in this group.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>18201181</pmid><doi>10.1111/j.1742-1241.2007.01666.x</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1368-5031 |
| ispartof | International journal of clinical practice (Esher), 2008-03, Vol.62 (3), p.374-381 |
| issn | 1368-5031 1742-1241 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70288228 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Alanine Transaminase - blood Biological and medical sciences Clinical outcomes Cohort Studies Drug therapy Dyslipidemias - diet therapy Dyslipidemias - drug therapy Fatty Liver - diet therapy Fatty Liver - drug therapy Female General aspects Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Life Style Lipids - blood Liver diseases Male Medical sciences Metabolic diseases Middle Aged Nutrition therapy Regression Analysis Retrospective Studies Statins Treatment Outcome Weight control Weight Loss - physiology |
| title | Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T18%3A16%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Weight%20loss,%20dietary%20advice%20and%20statin%20therapy%20in%20non-alcoholic%20fatty%20liver%20disease:%20a%20retrospective%20study&rft.jtitle=International%20journal%20of%20clinical%20practice%20(Esher)&rft.au=Riley,%20P.&rft.date=2008-03&rft.volume=62&rft.issue=3&rft.spage=374&rft.epage=381&rft.pages=374-381&rft.issn=1368-5031&rft.eissn=1742-1241&rft_id=info:doi/10.1111/j.1742-1241.2007.01666.x&rft_dat=%3Cproquest_pubme%3E1423391431%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=229918967&rft_id=info:pmid/18201181&rfr_iscdi=true |